Market Cap$360.08B
P/E19.73x
PEG Ratio2.73
Div yield2.87%
Beta0.12
MRK Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)11.76%
Price vs S&P 500 (4W)-1.05%
PEG Ratio2.73
VGM Score58.58
P/E Ratio (Annual)19.73x
Indicated Dividend Yield (Annual)2.87%
MRK Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.26 | -$0.13 | +49.43%(+$0.13) | |
| Q1 2026 | -$1.47 | -$1.28 | +13.15%(+$0.19) | |
| Q4 2025 | $2.01 | $2.04 | +1.47%(+$0.03) | |
| Q3 2025 | $2.35 | $2.58 | +9.85%(+$0.23) | |
| Q2 2025 | $2.03 | $2.13 | +5.04%(+$0.10) |
MRK Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.94
3.94
3.94
3.94
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
| BMYBristol-Myers Squibb Co. | B | B | B | 2.5x | 3.1% | 71.7% | — | $59.75 |
About Merck & Co., Inc.
Merck is a diversified pharmaceutical company with a leading immuno-oncology franchise anchored by Keytruda, a substantial vaccine business including Gardasil, and cardiometabolic disease treatments. The company also operates animal health segments globally, with 47% of revenue derived from US human pharmaceuticals and vaccines.